Kevin Patrick Danahy - Mar 17, 2022 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Chief Executive Officer
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol: PLSE
Transactions as of: Mar 17, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/24/2023, 04:31 PM
Previous filing: Mar 22, 2022
Next filing: Sep 27, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Stock Option (right to buy)	Award	$0	+25K		$0.00	25K	Mar 17, 2023	Common Stock	25K	$6.41	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 14, 2022, the reporting person was granted an option to purchase 150,000 shares of the Issuer's common stock. The option vests upon the achievement of performance objectives, with vesting targets of 25% vesting per year upon achievement of said objectives established by the Issuer's Compensation Committee, subject to the reporting person's continued service through each vesting date. The performance objectives for 2022 were met, resulting in the vesting of the option as to 25,000 shares.

Content

On February 14, 2022, the reporting person was granted an option to purchase 150,000 shares of the Issuer's common stock. The option vests upon the achievement of performance objectives, with vesting targets of 25% vesting per year upon achievement of said objectives established by the Issuer's Compensation Committee, subject to the reporting person's continued service through each vesting date. The performance objectives for 2022 were met, resulting in the vesting of the option as to 25,000 shares.